Advertisement.

MTCR Projected Dividend Yield

Metacrine Inc ( OTCBB : MTCR )

Metacrine is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with gastrointestinal, or GI, diseases. Co.'s program, MET642, targets the farnesoid X receptor, or FXR, which is central to modulating GI and liver diseases. Co. is developing another FXR agonist, MET409, for the treatment of non-alcoholic steatohepatitis, or NASH, a liver disease characterized by excess liver fat, inflammation and fibrosis. Co. is also developing small molecule inhibitors of hydroxysteroid dehydrogenase 17b13, or HSD17ß13, for the treatment of NASH. HSD17ß13 is a genetically validated target for liver disease.

12 YEAR PERFORMANCE RESULTS

MTCR Dividend History Detail
MTCR Dividend News
MTCR Competitors News

# of Shares: 0

Closing Price: 0.58

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
2026	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.58
Dividend 1 Yr Growth = ( 0.00 – 0.58 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.58

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
2023	N/A	Jun 21, 2023	Jun 15, 2023	Jun 20, 2023	0.5800
2023 Total:					0.5800